Carlo Selmi Selected Research

Disease Progression

2/2023	Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.
10/2021	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
5/2011	Primary biliary cirrhosis.
8/2009	Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity.
9/2007	Genetic polymorphisms of transforming growth factor beta-1 promoter and primary biliary cirrhosis in Japanese patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlo Selmi Research Topics

Disease

52	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 01/2002
39	Autoimmune Diseases (Autoimmune Disease) 04/2024 - 07/2003
32	Rheumatoid Arthritis 04/2024 - 10/2010
29	Inflammation (Inflammations) 12/2023 - 01/2006
18	Neoplasms (Cancer) 09/2023 - 08/2004
17	Psoriatic Arthritis 05/2024 - 04/2014
16	Infections 03/2022 - 04/2005
15	COVID-19 03/2024 - 01/2020
15	Systemic Scleroderma (Systemic Sclerosis) 11/2023 - 12/2005
12	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2023 - 05/2006
11	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2023 - 11/2014
11	Myositis (Idiopathic Inflammatory Myopathies) 01/2023 - 08/2015
11	Arthritis (Polyarthritis) 12/2022 - 04/2014
11	Liver Diseases (Liver Disease) 05/2022 - 06/2007
9	Dermatomyositis (Dermatopolymyositis) 08/2023 - 08/2013
8	Fibrosis (Cirrhosis) 01/2023 - 06/2005
8	Rheumatic Diseases (Rheumatism) 01/2023 - 03/2009
6	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 08/2023 - 08/2012
6	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016 - 10/2003
5	Pain (Aches) 01/2024 - 12/2012
5	Disease Progression 02/2023 - 09/2007
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2023 - 06/2014
5	Connective Tissue Diseases (Connective Tissue Disease) 01/2023 - 12/2017
5	Vasculitis (Vasculitides) 11/2022 - 02/2010
5	Polymyositis 01/2022 - 02/2017
5	Virus Diseases (Viral Diseases) 11/2021 - 05/2006
5	Obesity 01/2015 - 02/2008
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015 - 03/2010
5	Non-alcoholic Fatty Liver Disease 03/2014 - 02/2008
4	Pneumonia (Pneumonitis) 03/2024 - 12/2021
4	Respiratory Insufficiency (Respiratory Failure) 03/2024 - 10/2021
4	Axial Spondyloarthritis 01/2024 - 01/2017
4	Sjogren's Syndrome (Sjogren Syndrome) 02/2021 - 06/2015
4	Ankylosing Spondylitis 01/2021 - 04/2014
4	Atherosclerosis 01/2020 - 02/2013
4	Antisynthetase syndrome 11/2019 - 08/2015
4	Cryoglobulinemia 07/2019 - 05/2009
4	Multiple Sclerosis 08/2017 - 10/2010
4	Hypersensitivity (Allergy) 12/2014 - 03/2010
3	Spondylarthropathies 01/2024 - 08/2014
3	Skin Manifestations 04/2023 - 11/2014
3	Fever (Fevers) 01/2023 - 03/2022
3	Cholestasis 01/2022 - 10/2003
3	Thrombosis (Thrombus) 12/2021 - 01/2020
3	Necrosis 11/2021 - 05/2010
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2021 - 08/2012
3	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2021 - 08/2012
3	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019 - 01/2011

Drug/Important Bio-Agent (IBA)

55	AutoantibodiesIBA 09/2023 - 03/2005
42	AntibodiesIBA 10/2022 - 11/2004
19	Biomarkers (Surrogate Marker)IBA 01/2023 - 05/2006
16	CytokinesIBA 04/2024 - 06/2005
14	AntigensIBA 04/2023 - 08/2004
14	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2004
11	AutoantigensIBA 11/2021 - 03/2005
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2024 - 05/2010
8	Sodium Glutamate (Accent)IBA 11/2022 - 02/2008
8	Immunoglobulin G (IgG)IBA 03/2022 - 09/2009
7	VaccinesIBA 12/2023 - 03/2010
7	Etanercept (Enbrel)FDA Link 03/2022 - 12/2014
7	Immunoglobulin M (IgM)IBA 01/2018 - 04/2005
6	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 03/2024 - 01/2021
6	Immunoglobulin A (IgA)IBA 08/2023 - 06/2007
6	GlucocorticoidsIBA 04/2023 - 01/2022
6	MicroRNAs (MicroRNA)IBA 11/2021 - 08/2014
6	XenobioticsIBA 01/2010 - 11/2003
5	Janus KinasesIBA 05/2024 - 12/2014
5	Janus Kinase InhibitorsIBA 01/2024 - 08/2014
5	Immunosuppressive Agents (Immunosuppressants)IBA 08/2023 - 06/2011
5	Antinuclear AntibodiesIBA 01/2023 - 08/2005
5	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2023 - 12/2015
5	tocilizumab (atlizumab)FDA Link 01/2023 - 12/2014
5	Methotrexate (Mexate)FDA LinkGeneric 05/2022 - 11/2010
5	SteroidsIBA 01/2022 - 09/2015
5	InterferonsIBA 02/2021 - 05/2006
4	Interleukin-17 (Interleukin 17)IBA 04/2024 - 06/2015
4	Urokinase Plasminogen Activator ReceptorsIBA 03/2024 - 10/2021
4	Rheumatoid FactorIBA 01/2023 - 01/2018
4	Ligases (Synthetase)IBA 10/2022 - 08/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 05/2022 - 12/2012
4	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2009
4	Oxidoreductases (Dehydrogenase)IBA 01/2022 - 06/2006
4	Pyruvic Acid (Pyruvate)IBA 01/2022 - 06/2006
4	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2017 - 03/2013
4	Vitamin D FDA LinkGeneric 02/2015 - 03/2010
3	ChemokinesIBA 04/2024 - 01/2012
3	Interleukin-6 (Interleukin 6)IBA 04/2024 - 12/2014
3	RNA (Ribonucleic Acid)IBA 03/2024 - 02/2017
3	belimumabIBA 04/2023 - 12/2014
3	Ustekinumab (CNTO 1275)FDA Link 03/2023 - 01/2016
3	PlasminogenIBA 02/2023 - 10/2021
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2023 - 10/2021
3	Pyruvate Dehydrogenase Complex (Dehydrogenase Complex, Pyruvate)IBA 01/2022 - 03/2009
3	Immunoglobulins (Immunoglobulin)IBA 05/2021 - 01/2009
3	Interleukin-23 (Interleukin 23)IBA 01/2021 - 09/2018
3	Monoclonal AntibodiesIBA 01/2021 - 03/2009
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020 - 05/2012
3	apremilastIBA 01/2020 - 12/2018

Therapy/Procedure

23	Therapeutics 03/2024 - 03/2006
4	Biological Therapy 01/2020 - 03/2014